Tempus Unveils Its Scalable Tumor Organoid Screening Platform In Cell Reports Study
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced publication of a study outlining the precision medicine applications for its patient-derived tumor organoid (TO) platform. The study demonstrates how the platform has the potential to accelerate the application of patient derived biological models (organoids) in precision oncology and targeted therapeutic profiling programs […]


